Eltromin
Generic Name
Eltrombopag
Manufacturer
Beacon Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| eltromin 50 mg tablet | ৳ 900.00 | N/A |
Description
Overview of the medicine
Eltrombopag is an oral thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in various conditions.
Uses & Indications
Dosage
Adults
Initial dose for ITP is 50 mg once daily. For SAA, initial dose is 50 mg once daily, adjusted based on platelet counts and clinical response.
Elderly
No specific dose adjustment is required for elderly patients based on age alone, but caution is advised due to potential decreased hepatic, renal, or cardiac function.
Renal_impairment
No dose adjustment is required for patients with renal impairment, but careful monitoring is recommended.
How to Take
Orally, once daily. Administer at least 2 hours before or 4 hours after calcium-containing antacids, dairy products, or other calcium-containing products.
Mechanism of Action
Eltrombopag stimulates the proliferation and differentiation of megakaryocytes from bone marrow stem cells by interacting with the thrombopoietin receptor (TPO-R), thereby increasing platelet production.
Pharmacokinetics
Onset
Platelet count increases typically observed within 1-2 weeks.
Excretion
Mainly excreted in feces (59%) and urine (31%) as metabolites.
Half life
Approximately 21-34 hours.
Absorption
Rapidly absorbed, peak plasma concentrations reached in 2-6 hours. Bioavailability is affected by food, especially high-calcium meals.
Metabolism
Primarily metabolized by CYP1A2, CYP2C8, and UGT1A1/3. Also undergoes cleavage by UDP-glucuronyltransferase.
Side Effects
Contraindications
- Hypersensitivity to eltrombopag or any component of the formulation.
- Severe hepatic impairment (Child-Pugh Class C) for chronic HCV-related thrombocytopenia.
Drug Interactions
CYP450 inhibitors/inducers
Potential for altered eltrombopag exposure; monitor platelet counts and adjust dose.
Statins (e.g., Rosuvastatin)
Eltrombopag is an OATP1B1 and BCRP inhibitor, can increase plasma concentrations of statins. Reduce statin dose if co-administered.
Other drugs that bind polyvalent cations (e.g., mineral supplements, foods)
Reduce eltrombopag absorption.
Antacids containing polyvalent cations (e.g., aluminum, calcium, magnesium, iron, selenium, zinc)
Reduce eltrombopag absorption. Take eltrombopag at least 2 hours before or 4 hours after these agents.
Storage
Store in a cool and dry place, below 30°C. Protect from light and moisture.
Overdose
In case of overdose, monitor platelet counts closely. If platelet counts become excessively high, discontinue eltrombopag and consider appropriate medical intervention to reduce thrombotic risk. Symptomatic and supportive care.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if the potential benefit outweighs the potential risk to the fetus. It is unknown if eltrombopag is excreted in human milk; caution is advised during breastfeeding.
Side Effects
Contraindications
- Hypersensitivity to eltrombopag or any component of the formulation.
- Severe hepatic impairment (Child-Pugh Class C) for chronic HCV-related thrombocytopenia.
Drug Interactions
CYP450 inhibitors/inducers
Potential for altered eltrombopag exposure; monitor platelet counts and adjust dose.
Statins (e.g., Rosuvastatin)
Eltrombopag is an OATP1B1 and BCRP inhibitor, can increase plasma concentrations of statins. Reduce statin dose if co-administered.
Other drugs that bind polyvalent cations (e.g., mineral supplements, foods)
Reduce eltrombopag absorption.
Antacids containing polyvalent cations (e.g., aluminum, calcium, magnesium, iron, selenium, zinc)
Reduce eltrombopag absorption. Take eltrombopag at least 2 hours before or 4 hours after these agents.
Storage
Store in a cool and dry place, below 30°C. Protect from light and moisture.
Overdose
In case of overdose, monitor platelet counts closely. If platelet counts become excessively high, discontinue eltrombopag and consider appropriate medical intervention to reduce thrombotic risk. Symptomatic and supportive care.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if the potential benefit outweighs the potential risk to the fetus. It is unknown if eltrombopag is excreted in human milk; caution is advised during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Pharmacies, hospitals
Approval Status
DGDA Approved
Patent Status
Off-patent (generic versions available)
Clinical Trials
Extensive clinical trials have demonstrated efficacy and safety in indicated patient populations. Ongoing post-marketing surveillance and studies continue to refine understanding.
Lab Monitoring
- Complete Blood Count (CBC) with platelet count (weekly until stable, then monthly)
- Liver function tests (ALT, AST, bilirubin) (baseline, then every 2 weeks during dose adjustment, then monthly once stable)
- Serum creatinine (baseline and periodically)
Doctor Notes
- Careful monitoring of platelet counts is essential to minimize the risk of thrombotic events.
- Liver function tests should be performed regularly, and dose adjustment or discontinuation may be necessary if abnormalities occur.
- Educate patients on the importance of adhering to dietary restrictions regarding calcium-containing products.
Patient Guidelines
- Take eltrombopag on an empty stomach, at least 2 hours before or 4 hours after meals or products containing calcium (e.g., dairy products, antacids).
- Do not chew or crush the tablet.
- Report any signs of liver problems (e.g., yellowing of skin/eyes, dark urine, unusual tiredness) or blood clots (e.g., swelling/pain in leg, sudden shortness of breath) to your doctor immediately.
Missed Dose Advice
If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not take a double dose to make up for a missed one.
Driving Precautions
May cause dizziness or fatigue. Patients should be advised to exercise caution when driving or operating machinery until they know how eltrombopag affects them.
Lifestyle Advice
- Avoid activities that could lead to injury or bleeding.
- Maintain a balanced diet and stay hydrated.
- Regularly consult with your physician for monitoring and adjustments.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Eltromin Brand
Other medicines available under the same brand name
